Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension

被引：12

作者：

Benza, Raymond L. ^{[1
]}

Langleben, David ^{[2
]}

Hemnes, Anna R. ^{[3
]}

Noordegraaf, Anton Vonk ^{[4
]}

Rosenkranz, Stephan ^{[5
]}

Thenappan, Thenappan ^{[6
]}

Hassoun, Paul M. ^{[7
]}

Preston, Ioana R. ^{[8
]}

Ghio, Stefano ^{[9
]}

Badagliacca, Roberto ^{[10
]}

Vizza, Carmine D. ^{[10
]}

Lang, Irene M. ^{[11
]}

Meier, Christian ^{[12
]}

Gruenig, Ekkehard ^{[13
]}

机构：

[1] Ohio State Univ Wexner Med Ctr, Dept Med, Columbus, OH 43210 USA

[2] McGill Univ, Jewish Gen Hosp, Ctr Pulm Vasc Dis, Div Cardiol, Montreal, PQ, Canada

[3] Vanderbilt Univ Sch Med, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA

[4] Vrije Univ Amsterdam Med Ctr, Pulm Dis, Amsterdam, Netherlands

[5] Cologne Univ Heart Ctr, Dept Cardiol, Cologne, Germany

[6] Univ Minnesota, Dept Med, Cardiovasc Div, Minneapolis, MN USA

[7] Johns Hopkins Univ, Pulm & Crit Care Med, Baltimore, MD USA

[8] Tufts Med Ctr, Pulm Crit Care & Sleep Med Div, Boston, MA USA

[9] Fdn IRCCS Policlin San Matteo, Div Cardiol, Pavia, Italy

[10] Sapienza Univ, Dept Cardiol, Rome, Italy

[11] Med Univ Vienna, Allgemeines Krankenhaus, Dept Internal Medicine 2, Div Cardiol, Vienna, Austria

[12] Global Med Affairs, Bayer AG, Berlin, Germany

[13] Heidelberg Univ Hosp, Ctr Pulm Hypertens, Thoraxklin Heidelberg gGmbH, Heidelberg, Germany

来源：

EUROPEAN RESPIRATORY REVIEW | 2022年 / 31卷 / 166期

关键词：

SOLUBLE GUANYLATE-CYCLASE; ENDOTHELIN-RECEPTOR ANTAGONIST; RIGHT HEART; EXERCISE CAPACITY; BOSENTAN TREATMENT; PROGNOSTIC VALUE; SILDENAFIL; PARAMETERS; MANAGEMENT; SURVIVAL;

D O I：

10.1183/16000617.0061-2022

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are progressive diseases that can lead to right heart failure and death. Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH, successful treatments should lead to improvements in RV parameters. Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of PAH and inoperable or persistent/recurrent CTEPH after pulmonary endarterectomy. This review examines the current evidence showing the effect of riociguat on the right ventricle, with particular focus on remodelling, function and structural parameters in preclinical models and patients with PAH or CTEPH.

引用

页数：12

共 50 条

[41] Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry
Halank, Michael
Humbert, Marc
Gomez Sanchez, Miguel-Angel
Pittrow, David
Hoeper, Marius
Gruenig, Ekkehard
Ghofrani, H. Ardeschir
Wirtz, Hubert
Klose, Hans
Ewert, Ralf
Lange, Tobias J.
Klotsche, Jens
Meier, Christian
Brunn, Monika
Simonneau, Gerald
EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[42] Budgetary Impact of Adding Riociguat to a US Health Plan for the Treatment of Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension
Burudpakdee, Chakkarin
Shah, Anshul
Joish, Vijay N.
Divers, Christine
Yaldo, Avin
AMERICAN HEALTH AND DRUG BENEFITS, 2014, 7 (09): : 479 - 486
[43] A Phase 2 Study of the Soluble Guanylate Cyclase Stimulator Riociguat in Patients with Chronic Thromboembolic Pulmonary Hypertension or Pulmonary Arterial Hypertension
Ghofrani, Hossein-Ardeschir
Hoeper, Marius M.
Halank, Michael
Meyer, F. Joachim
Staehler, Gerd
Behr, Juergen
Ewert, Ralf
Weimann, Gerrit
Grimminger, Friedrich
CIRCULATION, 2010, 122 (02) : E239 - E239
[44] Riociguat For The Treatment Of Pulmonary Arterial Hypertension And Chronic Thromboembolic Pulmonary Hypertension: Real-Life Data From The Expert Registry
Gall, H.
Ghofrani, H. -A.
Hoeper, M. M.
Humbert, M.
Gomez Sanchez, M. -A.
Pittrow, D.
Halank, M.
Grunig, E.
Wirtz, H.
Klose, H.
Ewert, R.
Lange, T.
Klotsche, J.
Vachiery, J. -L.
Nielsen-Kudsk, J. E.
Snijder, R.
Mascherbauer, R.
Ulrich, S.
Loffler-Ragg, J.
Cottin, V.
Tsangaris, I.
Peacock, A.
Meier, C.
Brunn, M.
Simonneau, G.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
[45] Promising clinical experience with Riociguat in inoperable Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension patients in a real life setting
Huber, C.
Sigmund, E.
Gruenberger, M.
Aichinger, J.
Steringer-Mascherbauer, R.
WIENER KLINISCHE WOCHENSCHRIFT, 2016, 128 : S305 - S305
[46] The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension
DeSouza, Shilpa A.
Preston, Ioana R.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (05) : 467 - 476
[47] Treatment of patients with chronic thromboembolic pulmonary hypertension: focus on riociguat
Smith, Zachary R.
Makowski, Charles T.
Awdish, Rana L.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 957 - 964
[48] Riociguat Improves Pulmonary Hemodynamics in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension
Tsai, Cheng-Hsuan
Wu, Cho-Kai
Kuo, Ping-Hung
Hsu, Hsao-Hsun
Chen, Zheng-Wei
Hwang, Juey-Jen
Ko, Chi-Lun
Huang, Yu-Sen
Lin, Yen-Hung
ACTA CARDIOLOGICA SINICA, 2020, 36 (01) : 64 - 71
[49] Pulmonary Artery Compliance in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: The Pulmonary Hypertension Association Registry
McCormick, A.
Krishnan, A.
Badesch, D. B.
Benza, R.
Bull, T. M.
De Marco, T.
Feldman, J. P.
Hemnes, A.
Hirsch, R.
Horn, E.
Kennedy, J.
Mathai, S. C.
McConnell, J. W.
Pugliese, S.
Sager, J. S.
Shlobin, O. A.
Simon, M.
Lammi, M. R.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
[50] The role of the right ventricle in pulmonary arterial hypertension
Noordegraaf, A. Vonk
Galie, N.
EUROPEAN RESPIRATORY REVIEW, 2011, 20 (122): : 243 - 253

← 1 2 3 4 5 →